https://www.selleckchem.com/products/TWS119.html
BCR-ABL1, resulting from t(9;22), is the oncogenic driver of chronic myeloid leukemia and the therapeutic target of the disease. Molecular studies have been the gold standard modality for patient assessment since the advent of tyrosine kinase inhibitor therapy. In spite of that, there are cytogenetic abnormalities that can render the disease unresponsive to conventional therapy, thus making cytogenetics an important component of patient management guidelines. We present a case of a Tajik, Afghan patient with chronic myeloid leukemia with
Mi piace
Commento
Condividi
